Chronic hepatitis B patients who achieve complete response with oral antiviral therapy are still at much higher risk of developing hepatocellular cancer compared to patients with inactive CHB, Korean researchers find.
The finding turns conventional thinking on its head as it is generally
stated that successful use of oral nucleso(t)ide analogues (NUCs)
decreases HCC risk, the authors from the Sungkyunkwan University School
of Medicine in Seoul said.
Involving over 2300 CHB patients, the study
showed 7.7% of those started on NUC therapy had developed HCC within 42
months compared with just 1.1% in the inactive CHB group.